Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.
Obesity is common in the general population and research has shown it can increase the risk of multiple sclerosis (MS), as well as increase diagnostic delays, explained Ruth Ann Marrie, MD, PhD, director of the Multiple Sclerosis Clinic at the University of Manitoba.
How do comorbidities like metabolic syndrome impact the risk of MS? For instance, what do we know about why metabolic syndrome results in longer diagnostic delays?
So, it's an important question and because obesity is so common in the general population, so we recognize now from a number of studies In the United States and Europe, for example, that obesity does increase your risk of multiple sclerosis. And we think that's in part related to the fact that our fat tissues or adipose tissue is metabolically active, it secretes pro-inflammatory cytokines and free fatty acids. And so, it confers an increased risk of MS. And as you mentioned, it is one of the factors that can increase diagnostic delays.
It has also been demonstrated to affect some of the parameters that clinicians seem to follow when we're following people with multiple sclerosis. So, brain atrophy seems to be greater, and individuals with multi Multiple Sclerosis who are obese than nonobese. If we're looking at the thickness of the retinal layer in the eye that also seems to thin more quickly in individuals who are obese so suggesting some important impacts on outcomes and in children with multiple sclerosis. A less common group but nonetheless an important one. There's at least one study that suggests that the response to disease-modifying therapies may not be as good in children who are obese, which may suggest we need to think differently about their treatment.
So, it's very important, both in terms of you know, confers risks. So what can we do to reduce the risk of MS, we could work on obesity, but once somebody is diagnosed with MS, it will be important to try and help individuals achieve, you know, healthier weight through physical activity, healthy eating and working with them around the strategies to sustain those behaviors and trying to prevent it and people who are not obese at the time of diagnosis trying to head that off from the beginning.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More